Liposome-based Codelivery of Doxorubicin and Curcumin for Overcoming Multi-drug Resistance
발표자
()
초록
내용
Multidrug resistance (MDR) is a major obstacle to the traditional cancer treatment using chemotherapeutic agents like doxorubicin (DOX). MDR affects drug dosage regimens as well as allows recurrence and metastasis of cancer. Because DOX can cause severe side effects when administered at high doses, it is important to use MDR modulator to make cells sensitive to DOX. In this work, we focused on liposome-based codelivery system containing curcumin (CUR) and DOX, focusing on CUR as an MDR modulator. Synergistic effect was maximized when the ratio of DOX and CUR is 1:1, and the synthesis of liposomal drugs was confirmed through HPLC. In addition, the successful MDR reversal effect and the ability to induce immunogenic cell death were demonstrated through rhodamine 123 assay, western blotting and immunofluorescence. Compared to the conventional DOX treatment, the dual drug treatment exhibits not only significantly improved anticancer effect but also outstanding immune responses.